CRISPR Therapeutics AG (CRSP) Preferred Stock Liabilities (2016)
CRISPR Therapeutics AG's Preferred Stock Liabilities history spans 2 years, with the latest figure at $1.2 million for Q3 2016.
- For Q3 2016, Preferred Stock Liabilities changed N/A year-over-year to $1.2 million; the TTM value through Sep 2016 reached $1.2 million, changed N/A, while the annual FY2015 figure was $1.2 million, N/A changed from the prior year.
- Preferred Stock Liabilities for Q3 2016 was $1.2 million at CRISPR Therapeutics AG, roughly flat from $1.2 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $1.2 million in Q4 2015 and bottomed at $1.2 million in Q4 2015.